메뉴 건너뛰기




Volumn 10, Issue 6, 2004, Pages 327-329

Enfuvirtide: A new class of antiretroviral therapy for HIV infection

Author keywords

ART; Enfuvirtide; Entry inhibitor; HIV therapy; Side effects

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

EID: 9444292849     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2004.01042.x     Document Type: Article
Times cited : (5)

References (29)
  • 1
    • 0142244854 scopus 로고    scopus 로고
    • Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
    • Ball RA, Kinchelow T (2003). Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 49: 826-831.
    • (2003) J Am Acad Dermatol , vol.49 , pp. 826-831
    • Ball, R.A.1    Kinchelow, T.2
  • 2
    • 0037692990 scopus 로고    scopus 로고
    • Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death
    • Barretina J, Blanco J, Armand-Ugon M et al (2003). Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir Ther 8: 155-161.
    • (2003) Antivir Ther , vol.8 , pp. 155-161
    • Barretina, J.1    Blanco, J.2    Armand-Ugon, M.3
  • 3
    • 0037866607 scopus 로고    scopus 로고
    • Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease
    • Behrens GM, Meyer-Olson D, Stoll M et al (2003). Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 17 Suppl 1: S149-S154.
    • (2003) AIDS , vol.17 , Issue.SUPPL. 1
    • Behrens, G.M.1    Meyer-Olson, D.2    Stoll, M.3
  • 4
    • 0037530225 scopus 로고    scopus 로고
    • Enfuvirtide access, administration, and patient education
    • Celano SA (2003). Enfuvirtide access, administration, and patient education. Hopkins HIV Rep 15: 1-12.
    • (2003) Hopkins HIV Rep , vol.15 , pp. 1-12
    • Celano, S.A.1
  • 5
    • 0036315615 scopus 로고    scopus 로고
    • Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: Patient satisfaction and impact on activities of daily living
    • Cohen CJ, Dusek A, Green J et al (2002). Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 16: 327-335.
    • (2002) AIDS Patient Care STDS , vol.16 , pp. 327-335
    • Cohen, C.J.1    Dusek, A.2    Green, J.3
  • 6
    • 0141620176 scopus 로고    scopus 로고
    • Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models
    • Cole SR, Hernan MA, Robins JM et al (2003). Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158: 687-694.
    • (2003) Am J Epidemiol , vol.158 , pp. 687-694
    • Cole, S.R.1    Hernan, M.A.2    Robins, J.M.3
  • 7
    • 0033856458 scopus 로고    scopus 로고
    • Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
    • Derdeyn CA, Decker JM, Sfakianos JN et al (2000). Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367.
    • (2000) J Virol , vol.74 , pp. 8358-8367
    • Derdeyn, C.A.1    Decker, J.M.2    Sfakianos, J.N.3
  • 8
    • 0642365752 scopus 로고    scopus 로고
    • European Commission approves Fuzeon following FDA approval - First HIV-fusion inhibitor in fight against HIV
    • European Commission (2003). European Commission approves Fuzeon following FDA approval - first HIV-fusion inhibitor in fight against HIV. Infection 31: 7-8.
    • (2003) Infection , vol.31 , pp. 7-8
  • 9
    • 12144288786 scopus 로고    scopus 로고
    • Predictive factors of virological response to primary antiretroviral treatment
    • Faucher JF, Challier B, Chirouze C et al (2004). Predictive factors of virological response to primary antiretroviral treatment. Presse Med 33: 310-315.
    • (2004) Presse Med , vol.33 , pp. 310-315
    • Faucher, J.F.1    Challier, B.2    Chirouze, C.3
  • 10
    • 0042769119 scopus 로고    scopus 로고
    • Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome
    • Gazzaruso C, Bruno R, Garzaniti A et al (2003). Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 21: 1377-1382.
    • (2003) J Hypertens , vol.21 , pp. 1377-1382
    • Gazzaruso, C.1    Bruno, R.2    Garzaniti, A.3
  • 11
    • 0035487486 scopus 로고    scopus 로고
    • T-20 phase III studies underway
    • Giles C (2001). T-20 phase III studies underway. Surviv News (Atlanta Ga) 12: 1-12.
    • (2001) Surviv News (Atlanta Ga) , vol.12 , pp. 1-12
    • Giles, C.1
  • 12
    • 1142310723 scopus 로고    scopus 로고
    • Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection
    • Hardy H, Skolnik PR (2004). Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 24: 198-211.
    • (2004) Pharmacotherapy , vol.24 , pp. 198-211
    • Hardy, H.1    Skolnik, P.R.2
  • 13
    • 0038187684 scopus 로고    scopus 로고
    • Novel therapies based on mechanisms of HIV-1 cell entry
    • Kilby JM, Eron JJ (2003). Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 348: 2228-2238.
    • (2003) N Engl J Med , vol.348 , pp. 2228-2238
    • Kilby, J.M.1    Eron, J.J.2
  • 14
    • 10744229122 scopus 로고    scopus 로고
    • A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults
    • Lalezari JP, DeJesus E, Northfelt DW et al (2003a). A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 8: 279-287.
    • (2003) Antivir Ther , vol.8 , pp. 279-287
    • Lalezari, J.P.1    DeJesus, E.2    Northfelt, D.W.3
  • 15
    • 0037471311 scopus 로고    scopus 로고
    • A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
    • Lalezari JP, Eron JJ, Carlson M et al (2003b). A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17: 691-698.
    • (2003) AIDS , vol.17 , pp. 691-698
    • Lalezari, J.P.1    Eron, J.J.2    Carlson, M.3
  • 16
    • 0042885473 scopus 로고    scopus 로고
    • Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients
    • Lalezari JP, Patel IH, Zhang X et al (2003e). Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol 28: 217-222.
    • (2003) J Clin Virol , vol.28 , pp. 217-222
    • Lalezari, J.P.1    Patel, I.H.2    Zhang, X.3
  • 17
    • 0036853552 scopus 로고    scopus 로고
    • T-20: A model for novel anti-HIV drugs in development
    • Laurence J (2002). T-20: a model for novel anti-HIV drugs in development. AIDS Read 12: 469-470.
    • (2002) AIDS Read , vol.12 , pp. 469-470
    • Laurence, J.1
  • 18
    • 0037849954 scopus 로고    scopus 로고
    • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
    • Lazzarin A, Clotet B, Cooper D et al (2003). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348: 2186-2195.
    • (2003) N Engl J Med , vol.348 , pp. 2186-2195
    • Lazzarin, A.1    Clotet, B.2    Cooper, D.3
  • 19
    • 2142827106 scopus 로고    scopus 로고
    • Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex
    • Locatelli GA, Campiani G, Cancio R et al (2004). Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex. Antimicrob Agents Chemother 48: 1570-1580.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 1570-1580
    • Locatelli, G.A.1    Campiani, G.2    Cancio, R.3
  • 20
    • 3543087801 scopus 로고    scopus 로고
    • Cutaneous injection site reactions to long-term therapy with enfuvirtide
    • Maggi P, Ladisa N, Cinori E et al (2004). Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother.
    • (2004) J Antimicrob Chemother
    • Maggi, P.1    Ladisa, N.2    Cinori, E.3
  • 21
    • 0038162585 scopus 로고    scopus 로고
    • Decline in the AIDS and death rates in the EuroSIDA study: An observational study
    • Mocroft A, Ledergerber B, Katlama C et al (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
    • (2003) Lancet , vol.362 , pp. 22-29
    • Mocroft, A.1    Ledergerber, B.2    Katlama, C.3
  • 22
    • 0037529119 scopus 로고    scopus 로고
    • Atherosclerosis and HIV in the highly active antiretroviral therapy era: Towards an epidemic of cardiovascular disease?
    • Mooser V (2003). Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS 17(Suppl. 1): S65-S69.
    • (2003) AIDS , vol.17 , Issue.SUPPL. 1
    • Mooser, V.1
  • 23
    • 10744233678 scopus 로고    scopus 로고
    • Differences in durability of treatment with initial PI-based regimens
    • Perez-Elias MJ, Moreno A, Moreno S et al (2003). Differences in durability of treatment with initial PI-based regimens. HIV Clin Trials 4: 391-399.
    • (2003) HIV Clin Trials , vol.4 , pp. 391-399
    • Perez-Elias, M.J.1    Moreno, A.2    Moreno, S.3
  • 24
    • 0037059049 scopus 로고    scopus 로고
    • Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
    • Reeves JD, Gallo SA, Ahmad N et al (2002). Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 99: 16249-16254.
    • (2002) Proc Natl Acad Sci USA , vol.99 , pp. 16249-16254
    • Reeves, J.D.1    Gallo, S.A.2    Ahmad, N.3
  • 25
    • 0642340674 scopus 로고    scopus 로고
    • US FDA approves new class of HIV therapeutics
    • Robertson D (2003). US FDA approves new class of HIV therapeutics. Nat Biotechnol 21: 470-471.
    • (2003) Nat Biotechnol , vol.21 , pp. 470-471
    • Robertson, D.1
  • 26
    • 0038078724 scopus 로고    scopus 로고
    • Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains
    • Roman F, Gonzalez D, Lambert C et al (2003). Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 33: 134-139.
    • (2003) J Acquir Immune Defic Syndr , vol.33 , pp. 134-139
    • Roman, F.1    Gonzalez, D.2    Lambert, C.3
  • 28
    • 1842458366 scopus 로고    scopus 로고
    • Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy
    • Verhofstede C, Noe A, Demecheleer E et al (2004). Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr 35: 473-483.
    • (2004) J Acquir Immune Defic Syndr , vol.35 , pp. 473-483
    • Verhofstede, C.1    Noe, A.2    Demecheleer, E.3
  • 29
    • 0036090585 scopus 로고    scopus 로고
    • Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    • Wei X, Decker JM, Liu H et al (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
    • (2002) Antimicrob Agents Chemother , vol.46 , pp. 1896-1905
    • Wei, X.1    Decker, J.M.2    Liu, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.